An FDA panel of health experts voted to support approval for mass production of Genzyme's Myozyme for the treatment of Pompe disease, a rare muscle disorder that can lead to fatal respiratory problems. The FDA panel members ruled, 16-1, that the drug was effective, and most recommended accelerated approval of Myozyme, so long as Genzyme was diligent with follow-up. Report [1]
Links:
[1] http://biz.yahoo.com/ap/081021/genzyme_fda_panel.html?.v=1